Psychostimulants for depression

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Candy, Bridget ^a   Jones, L ^b   Williams, R ^b   Tookman, A ^b   King, M ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; DEXAMPHETAMINE; IMIPRAMINE; ISOCARBOXAZID; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PLACEBO; PSYCHOSTIMULANT AGENT; SERTRALINE;

ADD ON THERAPY; ANOREXIA; ANXIETY; ASTHENIA; AUTOMUTILATION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INFECTION COMPLICATION; INSOMNIA; MONOTHERAPY; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; NERVOUSNESS; PSYCHOTHERAPY; QUALITY OF LIFE; REDUCED ENERGY; REMISSION; RESTLESSNESS; REVIEW; RHINITIS; RHINOPHARYNGITIS; SEXUAL AROUSAL DISORDER; SIDE EFFECT; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT; VERTIGO; WEIGHT CHANGE; WITHDRAWAL SYNDROME;

EID: 44949194886     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006722.pub2     Document Type: Review

References (139)

1. Cantello 1989 {published data only} Cantello R, Aguggia M, Gilli M, Delsedime M, Chiardo Cutin I, Riccio A, et al.Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the "hedonic" dopamine synapse. Journal of Neurology, Neurosurgery and Psychiatry 1989;52:724-31.
2. Cookson 1986 {published data only} Cookson J, Silverstone T. The effects of Methylamphetamine on Mood and Apetite in Depressed patients: A placebo-controlled study. International Clinical Psychopharmacology 1986;1:127-33.
3. DeBattista 2003 {published data only} DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunctmodafinil for the short-term treatment of fatigue and sleepiness in patients withmajor depressive disorder: a preliminary double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2003;64:1057-64.
4. Elizur 1979 {published data only} Elizur A, Wintner I, Davidson S. The clinical and psychological effects of pemoline in depressed patients. A controlled study. International Pharmacopsychiatry 1979;14:127-34.
5. Fava 2005 {published data only} *Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of clinical psychiatry 2005;66:85-93.
6. Fernandez 1995 {published data only} Fernandez F, Levy JK, Samley RH. Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine. International Journal of Psychaitry in Medicine 1995;25:53-67.
7. Hare 1962 {published data only} Hare EH, Dominian J, Sharpe L. Phenelzine and dexamphetamine in depressive illness: A comparative trial. British Medical Journal 1962;1:9-12.
8. Hare 1964 {published data only} *Hare EH, McCance C, McCormick WO. Imipramine and "Drinamyl" in depressive illness: A comparative trial. British Medical Journal 1964;1:818-20.
9. Kits 1970 {published data only} Kits TP, van Praag. A controlled study of the antidepressant effect of P-chloro-n-methylamphetamine, a compound with a selective effect on the central 5-hydroxytryptamine metabolism. Acta Psychiatrica Scandinavica 1970;46:365-73.
10. Lee 2005 {published data only} Lee H, Kim SW, Kim JM, Shin IS, Yang SY, Yoon JS. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Human Psychopharmacology 2005;20:97-104.
11. Mattes 1985 {published data only} Mattes JA. Methylphenidate in mild depression: A double-blind controlled trial. Journal of Clinical Psychiatry 1985;46:525-57.
12. Overall 1962 {published data only} Overall JE, Hollister LE, Pokorny AD, Casey JF, Katz G. Drug therapy in depressions: Controlled evaluation of imipramine, isocarboxide, dextroamphetamine-amobarbital and placebo. Clinical Pharmacoly Therapy 1962;3:16-22.
13. Patkar 2006 {published data only} Patkar AA, Massand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, et al.A randomized, double-blind, placebo-controlled trial of augnebtation with an extended release formulation of methylphenidate in outpatients with treatment resistant depression. Journal of Clinical Psychopharmacology 2006;26:653-6.
14. Postolache 1999 {published data only} Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, Londono JH. Early augmentation of sertraline with methylphenidate. Journal of Clinical Psychiatry 1999;2:123-4..
15. Reus 1979 {published data only} Reus VI, Silberman E, Post RM, Weingartner H. d-Amphetamine: effects on memory in a depressed population. Biological Psychiatry 1979;14:345-56.
16. Rickels 1970 {published data only} Rickels K, Gordon P, Gansman D, Charles W, Pereira-Ogan J, Hesbacher P. Pemoline and methylphenidate in mildly depressed outpatients. Clinical Pharmacology and Therapeutics 1970;11:698-710.
17. Rickels 1972 {published data only} Rickels K, Gingrich RL, McLaughlin FW, Morris RJ, Sablosky L, Silverman H, et al.Methylphenidate in mildly depressed outpatients. Clinical Pharmacology and Therapeutics 1972;13:595-601.
18. Robin 1958 {published data only} Robin AA, Wiseberg S. A controlled trial of methyl phenidate (Ritalin) in the treatment of depressive states. Journal of Neurology, Neurosurgery and Psychiatry 1958;21:55-7.
19. Silberman 1981 {published data only} Silberman EK, Reus VI, Jimerson DC, Lynott AM, Post RM. Heterogenity of Amphetamine response in depressed patients. American Journal of Psychiatry 1981;10:1302-7.
20. Vaishnavi 2006 {published data only} Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR. Modafinil for atypicall depression: effects of open-label and double-blind discontinuation treatment. Journal of Clinical Psychopharmacology 2006;26:373-8.
21. Wagner 2000 {published data only} Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2000;61:436-40.
22. Wallace 1995 {published data only} Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. American Journal of Psychiatry 1995;6:929-31.
23. Wheatley 1969 a {published data only} Wheatley D. Amphetamines in general practice: their use in depression and anxiety. Seminars in Psychiatry 1969;1:163-73.
24. Wheatley 1969 b {published data only} Wheatley D. Amphetamines in general practice: their use in depression and anxiety. Seminars in Psychiatry 1969;1:163-73..
25. Ballinger 1974 Ballinger BR, Presly A, Reid AH, Stevenson IH. The effects of hypnotics on imipramine treatment. Psychopharmacology 1974;39:267-74.
26. Blashki 1971 Blashki TG, Mowbray R, Davies B. Controlled trial of amitriptyline in general practice. British Medical Journal 1971;1:133-8.
27. Blashki TG, Mowbray R, Davies BM. A controlled trial of an antidepressant (amitriptyline) in general practice. V World Congress of Psychiatry, Nov 28-Dec 4, Ciudad De Mexico. 1971.
28. Brooks 2003 Brooks A, Aharonovich E, Nunes E. Early participation in relapse prevention therapy predicts abstinence in a randomized clinical trial of depramine with depressed cocaine abusers. Annual Scientific Meeting of the College on Problems of Drug Dependence, Bal Harbour, FL, June 15-19. 2003.
29. Buchsbaum 1977 Buchsbaum MS, Van Kammen DP, Murphy DL. Individual differences in average evoked responses to d- and l-amphetamine with and without lithium carbonate in depressed patients. Psychopharmacology 1977;51:129-35.
30. Buckman 1973 *Buckman J, Hain JD, Smith BM, Stevenson I. Controlled Interviews using drugs II. Comparisons between restricted and freer conditions. Archives of General Psychiatry 1973;29:623-7.
31. Camacho 2006 Camacho A, Ng B. Methylphenidate for alpha-interferon induced depression. Journal of Psychopharmacology 2006;20:687-9.
32. Capstick 1965 *Capstick N, Corbett M, PAre C, Linford Rees W. A comparative trial of diazepam (valium) and amylobarbitone. British Journal of Psychiatry 1965;111:517-9.
33. Carlson 1995 Carlson GA, Rapport MD, Kelly KL, Pataki CS. Methylphenidate and desipramine in hospitalized children with comorbid behaviour and mood disorders: separate and combined effects on behavior and mood. Journal of Child and Adolescent Psychopharmacology 1995;5:191-204.
34. Carlson 2004 Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder. Bipolar Disorders 2004;6:416-20.
35. Carroll 1995 Carroll KM, Nich C, Rounsaville BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. Journal of Nervous and Mental Disease 1995;183:251-9.
36. Christensen 1990 Christensen L. Dietary treatment of depression. Behavior Therapy 1990;21:183-94.
37. Ciraulo 2005 Ciraulo DA, Knapp C, Rotosen J, Sarid-Segal O, Ciraulo AM, Lo-Castro J, et al.Nefazodone treatment of cocaine deprendence with comorbid depressive symptoms. Addiction 2005;100:23-31.
38. Clauson 2004 Clauson AS, Elliott ES, Watson BD, Treacy J. Coadminstration of Phenelzine and Methylphenidate for treatment resistant depression. Annals of Pharmacotherpy 2004;38:508.
39. Coffey 1990 *Coffey CE, Figiel GS, Weiner RD, Saunders WB. Caffeine augmentation of ECT. American Journal of Psychiatry 1990;147:579-85.
40. Cornelius 1994 Cornelius JC. Fluoxetine versus placebo in depressed alcoholics. Psychopharmacology 1994;30:661.
41. Cornelius JR, Perkins KA, Salloum IM, Thase ME, Moss HB. Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients. Journal of Clinical Psychopharmacology 1999;19:183-4.
42. Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Ehler JG, Jarrett PJ, et al.Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacology Bulletin 1995;31:297- 303.
43. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, et al.Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacology Bulletin 1997;33:165-70.
44. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al.Fluoxetine in depressed alcoholics. A double-blind placebo-controlled trial. Archives of General Psychiatry 1997;54:700-5.
45. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Perel J, Thase ME. Double-blind fluoxetine in depressed alcoholics. 149th Annual Meeting of the American Psychiatric Association; Nay 4-9; New York, NY. 1996.
46. Cornelius JR, Salloum IM, Haskett RF, Daley DC, Cornelius MD, Thase ME, et al.Fluoxetine versus placebo in depressed alcoholics: A 1 year follow-up study. Addictive Behaviors 2000;25:307-10.
47. Salloum IM, Thase ME, Haskett RF, Daley DC, Jones Barlock A, Upsher C, et al.Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacology Bulletin 1998;34:117-21.
48. Daley 1998 Daley DC, Salloum IM, Zuckoff A, Kirisci L, Thase ME. Increasing treatment adherence among outpatients with depression and cocaine dependence: Results of a pilot study. American Journal of Psychiatry 1998;155:1611-3.
49. Darvill 1959 Darvill FT, Woolley S. Double-blind evaluation of methylphenidate (Ritalin) hydrochloride. JAMA 1959;169:1739-41.
50. de Wit 1987 de Wit, Uhlenhuth EH, Johanson CE. The reinforcing properties of amphetamine in overweight subjects and subjects with depression. Clinical Pharmacology and Therapeutics 1987;42:127-36.
51. Duval 1996 Duval F, Mokrani MC, Crocq MA, Jautz M, Bailey P, Diep TS, et al.Effect of anti-depressant medication on morning and evening thyroid function tests during a major depressive episode. Archives of General Psychiatry 1996;53:833-40.
52. Fava 2006 Fava M, Rush AJ. Current status of augmentation and combination treatment for major depressive disorder: a literature review and a proposal for a novel approach to imporive practice. Psychotherpay and Psychosomatics 2006;75:139-53.
53. Fawcett 1971 Fawett J, Siomonpoulos V. Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression. Archives of General Psychiatry 1971;25:247-55.
54. Fawcett 1972 Fawsett J, Maas JW, Dekirmenjian H. Depression and MHPG Excretion. Archives of General Psychiatry 1972;26:246-51.
55. Fawcett 1987 Fawcett J, Edwards JH, Kravitz HM, Jeffries H. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. Journal of Clinical Psychopharmacology 1987;7:295- 310.
56. Kravitz HM, Edwards JH, Fawcett J, Fogg L. Challenging the amphetamine challenge test: Report of antidepressant treatment study. Journal of Affective Disorders 1990;20:121-8.
57. Giannini 1986 Giannini AJ, Malone DA, Giannini MC, Price WA, Loiselle RH. Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine. Journal of Clinical Pharmacology 1986;26:211-4.
58. Grade 1998 Grade C, Redford B, Chrostowski J, Toussaint L, Blakewell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Archives of Physical Medicine and Rehabilitation 1998;79:1047-50.
59. Harris 1960 Harris JA, Robin AA. A controlled trial of Phenelzine in depressive reactions. Journal of Mental Science 1960;106:1432- 7.
60. Hicks 1994 Hicks P, Matthews TK, Riggs M. Caffeine and ECT in the treatment of depression. Psychopharmacology Bulletin 1994;30(1): 106.
61. Hinton 1959 Hinton JM. A comparison of Perphenazine, (Fentazin) Sodium Amylobarbitone and a placebo in anxious and depressed out-patients. British Journal of Psychiatry 1959;105:872-7.
62. Holiday 1965 Holiday AR, Joffe JR. A controlled evaluation of protriptyline conpared to a placebo and to methylphenidate hydrochloride. The Journal of New Drugs 1965;5:257-8.
63. Hornig-Rohan 2002 Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with ADD and depression. Progress in Neuropsychophramacology 2002;26:585-9.
64. Hunter 1967 Hunter JW, Owen S, Eksi A, Scott JF. A controlled cross-over study of trimipramine and amylobarbitone. British Journal of Psychiatry 1967;113:667-70.
65. Insel 1983a Insel TR, Hamilton JA. Guttmacher LB. Murphy DL. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology 1983;80:231-5.
66. Insel TR, Mueller ES, Gillin JC, Siever LJ, Murphy DL. Tricyclic response in obsessive compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1985;9:25-31.
67. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry 1983;40:605-12.
68. Jefferson JW, Greist JH, Perse TL, Rosenfeld R. Fluvoxamine associated mania/hypomania in patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology 1991;11:391-2.
69. Zahn TP, Insel TR, Murphy DL. Psychophysiological changes during pharmacological treatment of patients with obsessive compulsive disorder. British Journal of Psychiatry 1984;145:39-44.
70. Jacobson 1958 *Jacobson A. The use of ritalin in psychotherapy of depressions of the aged. Psychiatric Quarterly 1958;32:474-83.
71. Joffe 1991 Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 1991;11:237-41.
72. Kaplitz 1975 Kapltz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. Journal of the American Geriatrics Society 1975;23:271-6.
73. Kerenyi 1960 Kerenyi AB, Koranyi EK, Sarwer-Foner GJ. Depressive states and drugs-III. Use of methylphenidate in open psychiatric settings in office practice. Canadian Medical Association Journal 1960;83:1249-54.
74. Klein 1991 *Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biological Psychiatry 1991;30:973- 84.
75. Lader 1965 Lader MH, Bond AJ, James DC. Clinical comparison of anxiolytic drug therapy. Psychological Medicine 1974;4:381-7.
76. Lader 1974 Bond AJ, James DC, Lader MH. Sedative effects on physiological and psychological measures in anxious patients. Psychological Medicine 1974;4:374-80.
77. Landman 1958 Landman ME, Preisig R, Perlman M. A practical mood stimulant. The Journal of the Medical Society of New Jersey 1958;55:55-8.
78. Leonard 2004 Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology 2004;19:151-80.
79. Little 1989 *Little KY. Detecting acute drug effects. Biological Psychiatry 1989;25:645-7.
80. Little 1993 Little KY. D-Amphetamine versus methylphenidate effects in depressed inpatients. Journal of Clinical Psychiatry 1993;54:525-7.
81. London 1966 London AM, Schreiber ED. A controlled study of effects of group discussions and an anorexiant in outpatient treatment of obesity. Internal Medicine 65;1:80-92.
82. Lovett Doust 1959 Lovett Doust JW, Lewis DJ, Miller A, Sprott D, Wright RLD. Controlled asessment of antidepressant drugs including tofranil. Canadian Psychiatric Association Journal 1959;4:S191-S194.
83. Masand 1991 Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics 1991;32:203-8.
84. McDowell 2000 McDowell DM, Levin FR, Seracini AM, Nunes EV. Venlafaxine treatment of cocaine abusers with depressive disorders. American Journal of Drug and Alcohol Abuse 2000;26:25-31.
85. Meston 2004 Meston CM. A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction. Journal of Sex and Marital Therapy 2004;30:57-68.
86. Natale 1979 Natale M, Dahlberg CC. The effect of psychotomimetics on therapist patient matching of speech "rhythms". Journal of Communication Disorders 1979;12:45-52.
87. Naylor 1986 Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biological Psychiatry 1986;21:915-20.
88. Naylor 1987 Naylor GJ, Smith AH, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biological Psychiatry 1987;22:657-9.
89. Niederhofer 2002 Niederhofer H. Therapy resistant major depression: symptom improvement psychopharmacological combination of antidepressants and methyphenidate. Wiener Medizininische Wochenschrift 2002;152:578-80.
90. Padala 2005 Padala PR, Petty F, Bhatia SC. Methylphenidate may treat apathy independent depression. Annals of Pharmacotherpy 2005;39:1947-9.
91. Pataki 1993 Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM. Side effects of Methylphenidate and Desipramine alone and in combination in children. Journal of the American Academy of Child and Adolescent Psychiatry 1993;32:1065-72.
92. Post 1974 Post RM, Gillin JC, Wyatt RJ, Goodwin FK. The effect of orally adminstered cocaine on sleep of depressed patients. Psychopharmacologia 1974;37:59-66.
93. Quadri 1980 Quadri AA, Shalini K, Channabasavanna SM. D-Amphetamine as a predictor for response to imipramine and amitriptyline. Indian Journal of Psychiatry 1980;22:182-4.
94. Randall 2005 Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewelyn MB, File SE. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. Journal of Psychopharmacology 2005;19:647-60.
95. Rapport 1993 Rapport MD, Carlson GA, Kelly KL, Pataki C. Methylphenidate and desipramine in hospitalised children. Journal of American Academic Child and Adolescent Psychiatry 1993;32:333-41.
96. Rees 1961 Rees L, Davies B. A controlled trial of phenelzine in the treatment of severe depressive illness. Journal of Mental Science 1961;107:560.
97. Riddle 1995 Riddle MA, Lynch KA, Scahill L, de Vries A, Cohen DJ, Leckman JF. Methylphenidate discontinuation and reinintiation during long-term treatment of children with Tourette's Disorder and attention deficit disorder: a pilot study. Journal of Child and Adolescent Psychopharmacology 1995;5:205-14.
98. Rosenquist 1994 Rosenquist PB, McCall WV, Farah A, Reboussin DM. Effects of caffeine pretreatment on measures of seizure impact. Convulsive Therapy 1994;10:181-5.
99. Roy-Byrne 1983 Roy-Byrne PP, Gwirtsman HE, Baxter L, Gerner RH. Endocrine correlates of mood response to methylphenidate in depression. Journal of Clinical Psychopharmacology 1983;3:266-8.
100. Schmitz 2001 Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug and Alcohol Dependence 2001;63:207-14.
101. Sramek 1995 Sramek JJ, Jasinsky O, Chang S, Shu V, Kashkin K, Kennedy S, et al.Pilot efficacy trial of ABT-200 in patients with major depressive disorder. Depression 1995;2:315-8.
102. Tremblay 2002 Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Archives of General Psychiatry 2002;59:409-16.
103. Tremblay 2002b *Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, Zack M, Busto UE. Brain reward system activity in major depression and comorbid nicotine dependence. Journal of Pharmacology and Experimental Therapeutics 2002.;302:1265-71.
104. Van Kammen 1975a Van Kammen DP, Murphy DL. Attenuation of the euphoriant and activating effects of d- and l-Amephetamine by lithium carbonate treatment. Psychopharmacologia 1975;44:215-24.
105. Van Kammen 1975b Gillin JC, Van Kammen DP, Graves J, Murphy D. Differential effects of D and L amphetamine on the sleep of depressed patients. Life Sciences 1975;17:1233-40.
106. Van Kammen 1978 Van Kammen DP, Murphy DL. Prediction of Imipramine antidepressant response by a one-day d-amphetamine trial. American Journal of Psychiatry 1978;135:1179-84.
107. Van Praag 1973 Van Praag HM, Korf J. 4-Chlorampetamines. Chance and Trend in the development of new antidepressants. Journal of Clinical Pharmacology and New drugs 1973;13:3-14.
108. Wheatley 1969c Wheatley D. Amphetamines in general practice: their use in depression and anxiety. Seminars in Psychiatry 1969;1:163-73.
109. Woods 1986 Woods SW, Tesar GE, Murray GB, Cassem NH. Psychostimulant treatment of depressive disorders secondary tomedical illness. Journal of Clinical Psychiatry 1986;47:12-5.
110. Ziedonis 1991a Ziedonis DM, Kosten TR. Depression as a prognostic factor for pharmacolgical treatment of cocaine dependence. Psychopharmacology Bulletin 1991;27:337-43.
111. Ziedonis 1991b Ziedonis DM, Kosten TR. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. Journal of Psychoactive Drugs 1991;23:417-25.
112. APA 2005 American Psychiatric Assocaition. Diagnostic and statisticsl manual of mental disorders (DSM-5). Washington, DC: Americian Psychiatric Association, 2005.
113. Bebbington 2000 Bebbington PE, Brugha TS, Meltzer H, Jenkins R, Ceresa C, Farell M, et al.Neurotic disorders and the recipt of psychiatric treatment. Psychological Medicine 2000;30:1369-76.
114. BNF 2007 British Medical Association and Royal Pharmaecutical Society of Great Britian. British National Formulary 53rd Edition. London: British Medical Assocaition and Royal Pharmaecutical Society od Great Britian, 2007.
115. Bosc 1997 Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European Neuropsychopharmacology 1997;7:S57 S79.
116. Cassano 2002 Cassano P, Fava M. Depression and public health. An overview. Journal of Psychosomatic Research 2002;53:849-57.
117. Chiarello 1987 Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Archives of General Psychiatry 1987;44:286-95.
118. Delgado 2000 Delgado PL. Depression: the case for a monoamine deficiency. Journal of Clinical Psychiatry 2000;61 Suppl 6:7-11.
119. Demyttenaere 2004 Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al.Prevalence, severity and unmet need for treatment of mental disorders in the World Health Organisation World Mental Health Surveys. JAMA 2004;291:2581-90.
120. Hamilton 1960 Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgy and Psychiatry 1960;23:56-62.
121. Higgins 2006 Higgins JPT, Greens S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (updated September 2006). www.cochrane.org/resoures/handbook/hbook.htm (accessed September 30th 2006). Wiley, 2006.
122. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clincal trials. BMJ 2001;323:42-6.
123. Lin 1999 Lin E, Parikh SV. Sociodemographic, clinical, and attitudinal characteristics of the untreated depressed in Ontario. Journal of Affective Disorders 1999;53:153-62.
124. Linet 1989 Linet LS. Treatment of a refractory depression with a coombination of fluoxetine and d-amphetamine. American Journal of Psychiatry 1989;146:803-4.
125. Maddox 1994 Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. Journal of Psychopharmacology 1994;8:48-53.
126. Masand 1998 Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation anti-depressants: A case series. Depression and Anxiety 1998;7(2):89-91.
127. Moncrieff 2005 Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331:155-7.
128. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
129. Murray 1997 Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Golbal Burden of Disease Study. Lancet 1997;349:1498-04.
130. Nguyen 2005 Nguyen B, Tampi RR. Psychostimulants in the treatment of depression in the older patient. Clinical Geriatrics 2005;13:39-45.
131. NICE 2004 National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical practice guideline No 23. London: National Institute for Clinical Excellence, 2004.
132. Orr 2007 Orr K, Taylor D. Psychostimulants in the treatment of depression. CNS Drugs 2007;21:239-57.
133. Satel 1989 Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. Journal of Clinical Psychiatry 1989;50:2491-2.
134. Singleton 2001 Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric morbidity among adults living in private households, 2000. London: The Stationery Office, 2001.
135. Spitzer 1995 Spitzer RL, Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV 3rd, et al.Health-related quality of life in primary care patients with mental disorders. JAMA 1995;274:1511-7.
136. Thomas 2003 Thomas CM, Morris S. Cost of depression among adults in England in 2000. British Journal of Psychiatry 2003;183:514-9.
137. Wang 2005 Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States. Archives of General Psychiatry 2005;62:629-40.
138. Ware 1992 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30:473-83.
139. Young 2001 Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United Sates. Archives of General Psychiatry 2001;58:55-61.